Nain Bio was invited to participate in the poster presentation

On February 13, 2025 Nain Bio, a leading global biopharmaceutical company focused on addressing the challenge of tumor drug resistance , reported that preclinical research results from its independently developed small molecule modulator targeting the PDIA6/IRE1 protein interaction will be presented as a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, held in Chicago, USA, April 25-30, 2025 (Press release, Nain Biotech, FEB 13, 2025, View Source [SID1234654626]). This groundbreaking research provides a new target and therapeutic strategy for selectively enhancing the sensitivity of tumor cells to endoplasmic reticulum stress (ER stress ) and inducing regulated cell death in tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Research Highlights:
Poster Topic: Development of a first-in-class PDIA6/IRE1 modulator for selectively sensitizing cancer cells to ER stress and regulated cell death.
Conference Section: Experimental and Molecular Therapeutics.
Panel Discussion: Novel Antitumor Agents 2.
Presentation Time: April 28, 2025, 2:00 PM–5:00 PM (Central Time).
Presentation Location: Booth 21, Poster #14 (Abstract #3045).

As the world’s oldest and largest academic oncology conference, the AACR (Free AACR Whitepaper) Annual Meeting has always been a touchstone for the development of innovative drugs. The inclusion of this research result not only validates Nain Bio’s original innovation capabilities in the field of tumor drug resistance , but also highlights the significant clinical translational value of this drug candidate. By precisely regulating the endoplasmic reticulum stress pathway , the company’s R&D team has opened up a new therapeutic dimension for overcoming tumor drug resistance .